Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice

TAP 标记的敲入小鼠中定义的红细胞 Krupple 样因子复合物

基本信息

  • 批准号:
    7268252
  • 负责人:
  • 金额:
    $ 35.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-06-15 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Erythroid Krupple Like Factor (EKLF) is the only known erythroid-specific transcription factor, and this zinc finger protein is essential for correct gamma to beta-globin gene switching. Although EKLF was discovered a number of years ago and much has been learned about its function, large gaps still exist in our understanding of the way in which this critical transcription factor regulates globin gene expression in vivo. A more detailed understanding of the mechanism of EKLF action will provide insights into globin gene regulation and will suggest novel methods for maintaining or reactivating human fetal globin gene expression in patients with hemoglobinopathies such as beta-thalassemia and sickle cell disease. A novel model for globin gene switching that is consistent with the EKLF binding profile described in this proposal is as follows. EKLF forms different complexes in primitive and definitive erythroid cells and these different complexes direct globin gene switching. In primitive cells, the EKLF complex binds to ?y2, ?h1 and ?-major/minor globin gene CACCC boxes equivalently; however, ?y2 and ?h1 genes are preferentially expressed because these genes are more proximal to the LCR. In definitive cells, a new EKLF complex is formed (perhaps as a result of the 3-fold increase in EKLF protein levels) and this complex binds specifically to the adult gene CACCC boxes. In this case, the more distal adult genes preferentially interact with the LCR and are consequently expressed at high levels. The central hypothesis of this proposal is that EKLF complexes in primitive and definitive erythroid cells are different and that these differences are essential for correct globin gene switching. The Specific Aims designed to test this hypothesis are: 1. To affinity tag the endogenous EKLF transcription factor gene with several Tandem Affinity Purification (TAP) tags and to produce mice that are homozygous for this modification. 2. To purify protein complexes from primitive and definitive erythroid tissues of the TAP tagged mice and to define the components of these complexes by mass spectrometry. 3. To determine the role of EKLF complexes in globin gene switching. These experiments will provide new mechanistic insights into globin gene switching and should provide a foundation for the development of new therapies for hemoglobinopathies such as sickle cell disease.
描述(由申请人提供):红系Krupple样因子(EKLF)是唯一已知的红系特异性转录因子,这种锌指蛋白对于正确的γ-珠蛋白至β-珠蛋白基因转换是必需的。虽然EKLF被发现了数年前,已经了解了很多关于它的功能,仍然存在很大的差距,在我们的理解中,这一关键的转录因子调节珠蛋白基因的表达在体内。更详细地了解EKLF的作用机制将提供珠蛋白基因调控的见解,并将提出新的方法来维持或重新激活血红蛋白病患者,如β-地中海贫血和镰状细胞病的人胎儿珠蛋白基因的表达。一种新的珠蛋白基因转换模型,这是与EKLF结合在这个建议中描述的档案是一致的如下。EKLF在原始和定形红系细胞中形成不同的复合物,这些不同的复合物指导珠蛋白基因转换。在原始细胞中,EKLF复合物与?y2,?H1和?主要/次要珠蛋白基因CACCC盒等效;然而,?Y2和?h1基因优先表达,因为这些基因更接近LCR。在定形细胞中,形成新的EKLF复合物(可能是EKLF蛋白水平增加3倍的结果),该复合物特异性结合成人基因CACCC盒。在这种情况下,更远端的成体基因优先与LCR相互作用,因此以高水平表达。该建议的中心假设是原始和定形红系细胞中的EKLF复合物是不同的,并且这些差异对于正确的珠蛋白基因转换是必需的。测试这一假设的具体目的是:1。用几个串联亲和纯化(TAP)标签亲和标记内源性EKLF转录因子基因,并产生这种修饰的纯合小鼠。2.从TAP标记小鼠的原始和定形红系组织中纯化蛋白复合物,并通过质谱法确定这些复合物的组分。3.探讨EKLF复合物在珠蛋白基因转换中的作用。这些实验将为珠蛋白基因转换提供新的机制见解,并为血红蛋白病(如镰状细胞病)的新疗法的开发提供基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TIM M. TOWNES其他文献

TIM M. TOWNES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TIM M. TOWNES', 18)}}的其他基金

Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice
TAP 标记的敲入小鼠中定义的红细胞 Krupple 样因子复合物
  • 批准号:
    8010041
  • 财政年份:
    2010
  • 资助金额:
    $ 35.65万
  • 项目类别:
Gene Replacement Therapy in Induced Pluripotent Stem (iPS) Cells for Treatment of
诱导多能干细胞 (iPS) 中的基因替代疗法用于治疗
  • 批准号:
    7676629
  • 财政年份:
    2008
  • 资助金额:
    $ 35.65万
  • 项目类别:
Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice
TAP 标记的敲入小鼠中定义的红细胞 Krupple 样因子复合物
  • 批准号:
    7448566
  • 财政年份:
    2007
  • 资助金额:
    $ 35.65万
  • 项目类别:
Human Globin Gene Regulation During Development
发育过程中的人类珠蛋白基因调控
  • 批准号:
    8699756
  • 财政年份:
    2007
  • 资助金额:
    $ 35.65万
  • 项目类别:
Human Globin Gene Regulation During Development
发育过程中的人类珠蛋白基因调控
  • 批准号:
    8510632
  • 财政年份:
    2007
  • 资助金额:
    $ 35.65万
  • 项目类别:
Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice
TAP 标记的敲入小鼠中定义的红细胞 Krupple 样因子复合物
  • 批准号:
    7655519
  • 财政年份:
    2007
  • 资助金额:
    $ 35.65万
  • 项目类别:
Human Globin Gene Regulation During Development
发育过程中的人类珠蛋白基因调控
  • 批准号:
    8308798
  • 财政年份:
    2007
  • 资助金额:
    $ 35.65万
  • 项目类别:
GENETIC STRATEGIES FOR CORRECTING SICKLE CELL DISEASE
纠正镰状细胞病的遗传策略
  • 批准号:
    6669243
  • 财政年份:
    2002
  • 资助金额:
    $ 35.65万
  • 项目类别:
GENETIC STRATEGIES FOR CORRECTING SICKLE CELL DISEASE
纠正镰状细胞病的遗传策略
  • 批准号:
    6584658
  • 财政年份:
    2002
  • 资助金额:
    $ 35.65万
  • 项目类别:
PILOT--SILENCING OF TRANSGENES BY HISTONE DEACETYLASE
试点——通过组蛋白去乙酰化酶沉默转基因
  • 批准号:
    6564373
  • 财政年份:
    2002
  • 资助金额:
    $ 35.65万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 35.65万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 35.65万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 35.65万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了